JP2013523686A5 - - Google Patents

Download PDF

Info

Publication number
JP2013523686A5
JP2013523686A5 JP2013501816A JP2013501816A JP2013523686A5 JP 2013523686 A5 JP2013523686 A5 JP 2013523686A5 JP 2013501816 A JP2013501816 A JP 2013501816A JP 2013501816 A JP2013501816 A JP 2013501816A JP 2013523686 A5 JP2013523686 A5 JP 2013523686A5
Authority
JP
Japan
Prior art keywords
vaccine according
polypeptide
vaccine
antigen
particles
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2013501816A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013523686A (ja
JP5942296B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2011/054866 external-priority patent/WO2011120994A1/en
Publication of JP2013523686A publication Critical patent/JP2013523686A/ja
Publication of JP2013523686A5 publication Critical patent/JP2013523686A5/ja
Application granted granted Critical
Publication of JP5942296B2 publication Critical patent/JP5942296B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2013501816A 2010-03-29 2011-03-29 少なくとも1つのcxxcモチーフを含むポリペプチドと異種抗原とを含む医薬組成物、及びその使用 Expired - Fee Related JP5942296B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP10305317 2010-03-29
EP10305317.9 2010-03-29
PCT/EP2011/054866 WO2011120994A1 (en) 2010-03-29 2011-03-29 Pharmaceutical compositions comprising a polypeptide comprising at least one cxxc motif and heterologous antigens and uses thereof

Publications (3)

Publication Number Publication Date
JP2013523686A JP2013523686A (ja) 2013-06-17
JP2013523686A5 true JP2013523686A5 (OSRAM) 2014-05-15
JP5942296B2 JP5942296B2 (ja) 2016-06-29

Family

ID=42312972

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2013501816A Expired - Fee Related JP5942296B2 (ja) 2010-03-29 2011-03-29 少なくとも1つのcxxcモチーフを含むポリペプチドと異種抗原とを含む医薬組成物、及びその使用

Country Status (12)

Country Link
US (1) US9801927B2 (OSRAM)
EP (2) EP3156068B1 (OSRAM)
JP (1) JP5942296B2 (OSRAM)
KR (1) KR101866301B1 (OSRAM)
CN (1) CN103002909B (OSRAM)
AR (1) AR081809A1 (OSRAM)
BR (1) BR112012024872B1 (OSRAM)
CA (1) CA2792174C (OSRAM)
ES (1) ES2619077T3 (OSRAM)
SG (1) SG183977A1 (OSRAM)
UY (1) UY33297A (OSRAM)
WO (1) WO2011120994A1 (OSRAM)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2476435T (pt) 2006-08-11 2018-03-05 Life Sciences Res Partners Vzw Péptidos imunogénicos e a sua utilização em distúrbios imunitários
US8999346B2 (en) 2008-02-14 2015-04-07 Life Sciences Research Partners Vzw Immunogenic control of tumours and tumour cells
WO2009101204A2 (en) * 2008-02-14 2009-08-20 Life Sciences Research Partners Vzw Elimination of immune responses to viral vectors
US9248171B2 (en) * 2008-02-14 2016-02-02 Imcyse Sa Immunogenic peptides and their use in transplantation
CA2715611C (en) 2008-02-14 2018-03-13 Life Sciences Research Partners Vzw Immunotherapy targeting intracellular pathogens
WO2009101206A2 (en) * 2008-02-14 2009-08-20 Life Sciences Research Partners Vzw Strategies to prevent and/or treat immune responses to soluble allofactors
RU2615460C2 (ru) 2010-11-25 2017-04-04 Имнейт Сарл Иммуногенные пептиды для применения в профилактике и/или лечении инфекционных заболеваний, аутоиммунных заболеваний, иммунных ответов на аллогенные факторы, аллергических заболеваний, опухолей, отторжения трансплантата и иммунных ответов против вирусных векторов. используемых для генной терапии или генной вакцинации
GB201201511D0 (en) 2012-01-30 2012-03-14 Univ Leuven Kath Modified epitopes for boosting CD4+ T-cell responses
US9457096B2 (en) 2012-07-06 2016-10-04 Consejo Nacional De Investigaciones Cientificas Y Tecnicas (Concet) Protozoan variant-specific surface proteins (VSP) as carriers for oral drug delivery
JP2014212722A (ja) * 2013-04-24 2014-11-17 学校法人加計学園 八面体構造を有するb型肝炎ウイルス様粒子結晶
GB201309469D0 (en) 2013-05-28 2013-07-10 Imcyse Sa Detection of CD4+ T lymphocytes
GB201418433D0 (en) 2014-10-17 2014-12-03 Imcyse Sa Novel immunogenic peptides
US10729791B2 (en) * 2015-05-18 2020-08-04 Imcyse Sa Animal models for evaluating pharmaceutical compounds
EP3352782B1 (en) 2015-09-25 2021-03-31 ImCyse SA Improved methods and compounds for eliminating immune responses to therapeutic agents
KR20240015731A (ko) 2016-04-19 2024-02-05 임시스 에스에이 신규 면역원성 CD1d 결합 펩티드
JP7102430B2 (ja) 2017-03-09 2022-07-19 アンシス・エスア 糖尿病の治療のためのペプチド及び方法
EP4144752A1 (en) * 2021-09-02 2023-03-08 Sorbonne Universite Viral-like particles for the treatment or prevention of an infection by a coronaviridae virus

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6165469A (en) * 1988-01-13 2000-12-26 University Of Virginia Recombinant Entamoeba histolytica lectin subunit peptides and reagents specific for members of the 170 kD subunit multigene family
DE60041042D1 (de) * 1999-03-12 2009-01-22 Aventis Pasteur Chlamydia antigene und deren korrespondierende dna fragmente und verwendungen davon
EP1201750A1 (en) 2000-10-26 2002-05-02 Genopoietic Synthetic viruses and uses thereof
EP2392345A3 (en) 2002-07-18 2012-03-07 Cytos Biotechnology AG Hapten-carrier conjugates comprising virus like particles and uses thereof
US7943396B2 (en) * 2004-06-22 2011-05-17 The Regents Of The University Of California Peptide-coated nanoparticles with graded shell compositions
DE502004010408D1 (de) 2004-07-02 2009-12-31 Schoelly Fiberoptic Gmbh Vorrichtung und verwendung der vorrichtung zur aufnahme und verarbeitung eines bildes
WO2006026746A2 (en) 2004-08-31 2006-03-09 The Government Of United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods to separate and expand antigen-specific t cells
GB0426641D0 (en) * 2004-12-03 2005-01-05 Bioactive Protein Delivery The Protein delivery system
WO2007122388A2 (en) 2006-04-13 2007-11-01 Midatech Limited Nanoparticles containing three various ligands for providing immune responses against infectious agents
WO2008094197A2 (en) * 2006-07-27 2008-08-07 Ligocyte Pharmaceuticals, Inc. Chimeric influenza virus-like particles
PT2476435T (pt) * 2006-08-11 2018-03-05 Life Sciences Res Partners Vzw Péptidos imunogénicos e a sua utilização em distúrbios imunitários
EP2199301A1 (en) * 2008-12-19 2010-06-23 DKFZ Deutsches Krebsforschungszentrum Immunogenic polypeptides comprising a scaffold polypeptide and a L2 polypeptide or fragment thereof

Similar Documents

Publication Publication Date Title
JP2013523686A5 (OSRAM)
Medhi et al. Nanoparticle-based strategies to combat COVID-19
Syomin et al. Virus-like particles as an instrument of vaccine production
Baker et al. Designer oncolytic adenovirus: coming of age
US12472244B2 (en) Immunogenic compositions and uses thereof
Huang et al. Escherichia coli-derived virus-like particles in vaccine development
Yan et al. The application of virus-like particles as vaccines and biological vehicles
Lei et al. Bioinspired cell silicification: from extracellular to intracellular
Prange Host factors involved in hepatitis B virus maturation, assembly, and egress
SG131116A1 (en) Functional influenza virus-like particles (vlps)
EP2361930A3 (en) Multimers of MHC-peptide complexes and uses thereof in Borrelia infectious diseases
Zhou et al. Vaccine strategies for human papillomavirus-associated head and neck cancers
JP2012010713A5 (OSRAM)
JP2019513005A5 (OSRAM)
MX375379B (es) Receptores de celulas t anti - papilomavirus 16 e7 humano.
EP2525816A4 (en) PRESENTATION OF TARGETED HETEROLOGOUS ANTIGENS ON CALICIVIRUS VIRAL PSEUDO PARTICLES
EP3199545A3 (en) Computationally optimized broadly reactive antigens for h1n1 influenza
JP2020506690A5 (OSRAM)
JP2015524422A5 (OSRAM)
CN106008716A (zh) 呼吸道合胞病毒抗原组合物和方法
JP2016539641A5 (OSRAM)
JP2019536426A5 (OSRAM)
Chhikara et al. Viral infection mitigations using advanced nanomaterials and tools: lessons from SARS-CoV-2 for future prospective interventions
Alhashimi et al. Nonhuman adenoviral vector-based platforms and their utility in designing next generation of vaccines for infectious diseases
WO2012149160A3 (en) Viruses modified with unnatural moieties and methods of use thereof